PepGen Inc. - 8-K Filing
PepGen Inc. filed an updated Corporate Presentation on May 21, 2026, in connection with its participation in the International Myotonic Dystrophy Consortium from May 26-30, 2026. The presentation highlights PGN-EDODM1 for myotonic dystrophy type 1 (DM1), including data showing splicing correction and safety trends across dose cohorts up to 15 mg/kg in the FREEDOM study. Anticipated milestones include clinical results from the 10 mg/kg cohort in late 2026. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $PEPG